<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458143</url>
  </required_header>
  <id_info>
    <org_study_id>P2018/016</org_study_id>
    <nct_id>NCT03458143</nct_id>
  </id_info>
  <brief_title>Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval</brief_title>
  <official_title>Study of Respiratory Depression During Analgosedation Technique Combining Remifentanyl and Ketamine in TCI for Oocyte Retrieval</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of the addition of ketamine to a conscious sedation protocol
      including remifentanil during oocyte retrieval. The investigators will have 2 groups with
      different target effect site concentrations, namely 150 ng/ml and 200 ng/ml.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The actual protocol for conscious sedation during oocyte retrieval in at the Erasmus hospital
      (Brussels) consists of Remifentanil in TCI-mode, with premedication by Midazolam. However,
      episodes of bradypnaea with or without desaturation are still common.

      The primary objective is to observe if with the addition of ketamine, it is possible to
      significantly reduce the dose of Remifentanil, in order to avoid episodes of respiratory
      depression caused by the opioid.

      The secondary outcomes measured, will be the pain levels experienced by the patient, the
      sedation level, and the satisfaction of the patients after the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>respiratory depression</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>respiratory rate (number of inspiration per minute)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory depression</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>SpO2 (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>EVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>satisfaction scale: 1=unsatisfied. 2=average satisfaction 3=Satisfied 4=very satisfied. The higher the value, the better. Additionally, we ask the patients if they would choose the same anesthetic method, should it be necessary to repeat the procedure. If yes, it is considered a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>15 days after the oocyte retrieval</time_frame>
    <description>HCG in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ketamine dosage</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>blood sample (serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation level</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>OAAS: Observer's Assessment Of Alertness/Sedation Scale. 5=Responds readily to name spoken in normal tone. 4=Lethargic response to name spoken in normal tone. 3=Response only after name is called loudly and/or repeatedly. 2=Response only after mild prodding or shaking. 1=Response only after paintful trapezius squeeze. 0=No response after paintful trapezius squeeze. Values higher than 3 represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial pressure</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>Beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>NOL-index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>ANI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation level</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>Ramsay sedation scale. 1=Anxious and agitated or restless, or both. 2=Co-operative, oriented, and calm. 3=Responsive to commands only. 4=Exhibiting brisk response to light glabellar tap or loud auditory stimulus. 5=Exhibiting a sluggish response to light glabellar tap or loud auditory stimulus. 6=unresponsive. Values of 2-3 represent the better outcome.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Oocyte Retrieval</condition>
  <condition>Sedation, Conscious</condition>
  <condition>Ventilatory Depression</condition>
  <arm_group>
    <arm_group_label>ketamine 150 ng/ml</arm_group_label>
    <description>The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine 200 ng/ml</arm_group_label>
    <description>The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 150 ng/ml</intervention_name>
    <description>conscious sedation in TCI-mode</description>
    <arm_group_label>ketamine 150 ng/ml</arm_group_label>
    <other_name>conscious sedation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>conscious sedation in TCI-mode</description>
    <arm_group_label>ketamine 150 ng/ml</arm_group_label>
    <arm_group_label>ketamine 200 ng/ml</arm_group_label>
    <other_name>conscious sedation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oocyte retrieval</intervention_name>
    <description>Oocyte retrieval for In Vitro Fertilization</description>
    <arm_group_label>ketamine 150 ng/ml</arm_group_label>
    <arm_group_label>ketamine 200 ng/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine 200 ng/ml</intervention_name>
    <description>conscious sedation in TCI-mode</description>
    <arm_group_label>ketamine 200 ng/ml</arm_group_label>
    <other_name>conscious sedation</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma/Serum for Ketamine dosage after the procedure
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients in good health, with informed consent, undergoing oocyte retrieval at the
        Erasmus Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients having an oocyte retrieval

        Exclusion Criteria:

          -  BMI &gt; 30

          -  endometriosis

          -  contraindications to ketamine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peres-Bota Iulia, student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barvais Luc, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>Erasme Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>barvais luc, MD PhD</last_name>
    <phone>+3225553919</phone>
    <email>luc.barvais@erasme.ulb.ac.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasme University Hospital</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Barvais, phd</last_name>
      <email>Luc.Barvais@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Peres-Bota Iulia, student</last_name>
      <email>Iulia.Peres-bota@ulb.ac.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Luc Barvais</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>ketamine</keyword>
  <keyword>remifentanil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

